Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News ESC 2016

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

Todd Neale

August 31, 2016

News Opinion Editor's Corner

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

Shelley Wood

August 24, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

初期研究显示利伐沙班拮抗剂安全、有效

December 30, 2013

News Daily News

Rivaroxaban Antidote Appears Safe, Effective in Early Study

December 30, 2013

News Daily News

El Antídoto de Rivaroxaban parece Seguro y Eficaz en un Estudio Preliminar

December 30, 2013

Advertisement

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

初期研究显示利伐沙班拮抗剂安全、有效

Rivaroxaban Antidote Appears Safe, Effective in Early Study

El Antídoto de Rivaroxaban parece Seguro y Eficaz en un Estudio Preliminar

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content